CGON CG Oncology
- 28.500
- -1.520-5.06%
- 28.960
- +0.460+1.61%
CG Oncology News
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
Express News | CG Oncology Inc Q1 Shr View $-0.32 -- Lseg Ibes Data
Express News | CG Oncology Inc - Qtrly Shr Loss $0.36
CG Oncology 1Q Loss/Shr 36c >CGON
CG Oncology 1Q Loss/Shr 36c >CGON
Express News | CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
CG Oncology | 10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
CG Oncology's Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy Rating
75% of cancer patients have completely lost their tumors! Positive clinical results for CG Oncology (CGON.US) immunotherapy phase 3
CG Oncology (CGON.US) announced that it has obtained positive results in a phase 3 clinical trial of developing oncolytic virus therapy cretostimogene in the treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) patients who do not respond to BCG (BCG).
CG Oncology Reports Data From Phase 3 Bladder Cancer Study
Buy Rating Justified by CG Oncology's Cretosmogene Efficacy and Market Positioning
12 Health Care Stocks Moving In Friday's Intraday Session
GainersEliem Therapeutics (NASDAQ:ELYM) shares moved upwards by 32.8% to $11.14 during Friday's regular session. The market value of their outstanding shares is at $308.8 million. Ardelyx (NASDAQ:ARDX
Express News | CG Oncology Inc - Median Duration of Response (Dor) Was Not Reached in Study
Express News | CG Oncology Inc - Topline Data Expected From Bond-003 by End of 2024
Express News | CG Oncology Inc - Two Patients (1.8%) Had Serious Traes (Grade 2) in Study
Express News | CG Oncology Inc - There Were No Grade 3 or Higher Treatment-Related Adverse Events or Deaths Reported in Study
Express News | CG Oncology Inc - Cretostimogene Has Shown Durable Responses Over Time With Twenty-Nine Patients Maintaining a Complete Response for 12 Months or More
Express News | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining over 400 points on Friday.Shares of Amgen Inc. (NASDAQ:AMGN) rose sharply during Friday's session after the company reported better-than-expec
CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald
CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald
Analysis
Price Target
No Data
